Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
about
Long-acting beta2-agonists for chronic obstructive pulmonary diseaseLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisInhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary diseaseInhaled corticosteroids for stable chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta 2 -agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseInhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary diseaseInhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary diseaseLong-acting beta2-agonists for poorly reversible chronic obstructive pulmonary diseaseInhaled corticosteroids for stable chronic obstructive pulmonary diseasePneumocafé project: an inquiry on current COPD diagnosis and management among General Practitioners in Italy through a novel tool for professional education.Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trialEffects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPDEarly response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations.Phenotypes of chronic obstructive pulmonary disease.Salmeterol/fluticasone combination in the treatment of COPD.Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD.Pharmacological treatment of COPD.Daily home-based spirometry during withdrawal of inhaled corticosteroid in severe to very severe chronic obstructive pulmonary disease.Asthma and Chronic Obstructive Pulmonary Disease (COPD) - Differences and Similarities.Downregulation by a long-acting beta2-adrenergic receptor agonist and corticosteroid of Staphylococcus aureus-induced airway epithelial inflammatory mediator production.Caring for the burden of COPD.Impaired Hemorheology in Exacerbations of COPD.Treatment of dyspnoea in advanced cancer patients: ESMO Clinical Practice Guidelines.
P2860
Q24197467-57C3B6FE-8FD6-438F-96F9-0213DDA4EC46Q24197853-573AC466-2B5B-482C-A418-6C5F24C50AA6Q24197989-1D3BCE43-2EDC-4BEB-8158-7A72668B0FDEQ24199130-2732D473-7AB9-40D4-B6DF-C187F7118ABEQ24200446-69B660CA-FF01-418F-B488-3D4540897FB2Q24202092-A8F6DF09-CB96-452E-9F91-79E513813E23Q24202510-4F80EB3E-E930-4531-8373-27057AD86DA7Q24234164-6A7D2365-B89E-4382-BA65-F0F8304E0CBAQ24236037-1492C600-DA94-409E-B710-AB25A1B7A408Q24243515-D53747D9-B349-4973-A850-15957C148D22Q24243564-061334A6-6420-4335-B209-D147B925E22DQ24243613-B7F1FCEA-2E01-4D37-AF5B-60F08A029E67Q24245141-15BCB5EC-D9B7-4AFD-BC0F-1BADC4E67C33Q24245481-D9D800F4-5B4A-4BEC-BDFC-543C150B05E4Q33770577-34796D78-F500-435C-B188-23D86E7653F7Q35747036-4C1DD723-E5BF-4C2A-A68B-3ED998232E23Q35747040-DC2B5BD2-329D-448B-8C13-4BF81C1C1AF4Q36636050-EF4487EB-67EE-4851-928F-9E7E423CA6B5Q37008634-E2CEA977-A504-4AEF-9B7D-BF8709890DC5Q37018817-6616268A-57A0-4949-9146-5F0E2F6603CDQ37530843-74E6A97C-D886-4613-8548-C9F282D16809Q37924598-6102B588-EA18-4CCE-BF4A-65D4552DF925Q39437180-08C04DAD-85FF-4209-B5D0-1B9B74F68F96Q39670594-8B268B3A-B6A6-4EF7-9429-C335C38FE9E3Q40314061-D468E418-6941-460B-B327-35540EC6584DQ42744093-A96D9CCD-FCFD-4D21-982F-AE596618ED92Q47095483-FBC988F4-AFEA-4104-AC07-B098C3E9E78EQ53364790-DAD58E7A-A394-4DBC-95BE-410A04096E2D
P2860
Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Early onset of effect of salme ...... obstructive pulmonary disease.
@ast
Early onset of effect of salme ...... obstructive pulmonary disease.
@en
type
label
Early onset of effect of salme ...... obstructive pulmonary disease.
@ast
Early onset of effect of salme ...... obstructive pulmonary disease.
@en
prefLabel
Early onset of effect of salme ...... obstructive pulmonary disease.
@ast
Early onset of effect of salme ...... obstructive pulmonary disease.
@en
P2093
P2860
P356
P1433
P1476
Early onset of effect of salme ...... obstructive pulmonary disease.
@en
P2093
J A Anderson
P Calverley
TRISTSAN study group
P2860
P304
P356
10.1136/THX.2004.025411
P407
P577
2005-04-01T00:00:00Z